Loading
A phase 2/3 trial of regorafenib, aspirin and bevacizumab (glioblastoma use) in colorectal cancer, run by Centre Hospitalier Universitaire de Besancon, now recruiting.
Regorafenib With Low-dose Chemotherapies and Aspirin Followed by Standard Chemotherapies in Metastatic Colorectal Cancer is a phase 2/3, randomised interventional study registered as NCT05462613 by Centre Hospitalier Universitaire de Besancon, with a registry enrolment figure of 446 participants, started 2023-05-09 and due to reach its primary completion in 2029-11. Interventions recorded: quality of life questionnaires; Blood sample; Regorafenib; Metronomic chemotherapies; Aspirin; Bevacizumab; FOLFIRI or FOLFOX. Conditions listed: Metastatic Colorectal Cancer. Primary outcome: best objective response during treatment period (phase II); overall survival (OS) (phase III). Colorectal eligibility wording from the registry: "Patients with histologically proven metastatic colorectal cancer in progression after a first line of chemotherapy +/- targeted therapy". Sites: France. No results are recorded here; the registry entry is the source.
Shares Regorafenib, Bevacizumab (glioblastoma use), Anti-angiogenic therapy, Colon cancer (adenocarcinoma of the colon) and the tag colorectal-deep-dive.
Shares Regorafenib, Anti-angiogenic therapy, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Regorafenib, Anti-angiogenic therapy, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Regorafenib, Anti-angiogenic therapy, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Regorafenib, Anti-angiogenic therapy, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Regorafenib, Anti-angiogenic therapy, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Bevacizumab (glioblastoma use), Anti-angiogenic therapy, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Regorafenib, Bevacizumab (glioblastoma use), Anti-angiogenic therapy, Colon cancer (adenocarcinoma of the colon) and the tag colorectal-deep-dive.